Flag of the European Union EU Clinical Trials Register Help

Clinical trials for janssen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,471 result(s) found for: janssen. Displaying page 5 of 74.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-002785-12 Sponsor Protocol Number: 14724A Start Date*: 2013-03-20
    Sponsor Name:H. Lundbeck A/S
    Full Title: A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) DE (Completed) ES (Completed) CZ (Completed) EE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001956-22 Sponsor Protocol Number: CNTO1275CRD1001 Start Date*: 2017-01-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Double-blind Pharmacokinetic study of Ustekinumab in Pediatric Subjects with Moderately to Severely Active Crohn's Disease
    Medical condition: Moderately to severely active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PL (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004724-35 Sponsor Protocol Number: VX-950HPC3006 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000735-32 Sponsor Protocol Number: 56021927PCR3002 Start Date*: 2015-09-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Medical condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) RO (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005000-19 Sponsor Protocol Number: CNTO1275SLE2001 Start Date*: 2015-03-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006642-34 Sponsor Protocol Number: R076477-SCH-3018 Start Date*: 2007-06-07
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia
    Medical condition: Subjects 18 years of age or older who meet the DSM-IV criteria for schizophrenia, experiencing an acute schizophrenic episode with a PANSS total score at baseline higher or equal as 70 and admitted...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001065 Acute schizophrenia episode LLT
    9.1 10001064 Acute schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005139-14 Sponsor Protocol Number: 54767414SMM2001 Start Date*: 2015-05-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) CZ (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002210-22 Sponsor Protocol Number: COU-AA-003-EXT Start Date*: 2008-09-25
    Sponsor Name:Janssen Oncology, Inc.
    Full Title: An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA...
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006755-12 Sponsor Protocol Number: COU-AA-001Ext Start Date*: 2007-03-06
    Sponsor Name:Janssen Oncology, Inc.
    Full Title: An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002663-10 Sponsor Protocol Number: SSAT049 Start Date*: 2012-11-12
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV...
    Medical condition: HIV-1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004097-15 Sponsor Protocol Number: GabA-01 Start Date*: 2015-10-23
    Sponsor Name:Wilhelminenspital
    Full Title: A single center, prospective, randomized, double blind, placebo-controlled, three-way cross-over study of the analgesic effects of Midazolam versus Placebo with Fentanyl as an active control in hum...
    Medical condition: nociceptive pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000305-13 Sponsor Protocol Number: RIVAROXDVT3002/BAY59-7939/17261 Start Date*: 2014-07-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
    Medical condition: Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) IT (Completed) ES (Completed) NL (Completed) LT (Completed) BG (Completed) GR (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002022-37 Sponsor Protocol Number: CNTO1959PSO3006 Start Date*: 2016-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects ...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001683-29 Sponsor Protocol Number: 61393215MDD2001 Start Date*: 2019-09-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxio...
    Medical condition: Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000728-24 Sponsor Protocol Number: MEBENDAZOLGAI3003 Start Date*: 2016-03-01
    Sponsor Name: Janssen Research & Development, LLC
    Full Title: A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment o...
    Medical condition: Helminth infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-013403-55 Sponsor Protocol Number: NL2861002909 Start Date*: 2009-10-07
    Sponsor Name:VU university medical center
    Full Title: Early recognition and optimal treatment of delirium in patients with advanced cancer.
    Medical condition: Delirium in patients with advanced cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001176-10 Sponsor Protocol Number: CNTO136ARA3004 Start Date*: 2013-09-09
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNT...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) IT (Completed) DE (Prematurely Ended) PT (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) PL (Completed) HR (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005458-97 Sponsor Protocol Number: VAC18193RSV3001 Start Date*: 2021-10-28
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years an...
    Medical condition: Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004269-14 Sponsor Protocol Number: BIRD2018001 Start Date*: 2019-11-08
    Sponsor Name:Belgian IBD research and development
    Full Title: Loss of RESponse to Ustekinumab treated by dose Escalation
    Medical condition: Crohn’s disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001941-28 Sponsor Protocol Number: R092670PSY3015 Start Date*: 2018-02-28
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 07:54:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA